Intelligence Profile
Clinical Applications
Clinical Applications of N1087
N1087 is an investigational compound currently being evaluated for its potential use in the treatment of hair loss conditions, specifically androgenetic alopecia in men and female pattern hair loss.
Androgenetic Alopecia in Men:
According to the upcoming Phase 3 study (NCT07529977), researchers are assessing the efficacy and safety of oral Minoxidil (also referred to as N1087) in treating androgenetic alopecia. This condition is characterized by progressive hair thinning and is the most common cause of hair loss in men.
Female Pattern Hair Loss:
A separate Phase 3 trial (NCT07303322) is set to evaluate N1087 in women with female pattern hair loss, a similar condition that results in hair thinning primarily affecting the top and crown of the scalp.
While these trials are not yet recruiting, they highlight the focus on using N1087 for hair regrowth and stabilization of hair loss, aiming to provide a potentially new oral treatment option for these conditions.
The evidence specific to N1087 in these contexts consists of planned trials (not yet recruiting), meaning concrete clinical findings from these studies are not yet available. Therefore, further information will depend on the outcomes of these trials.
Disclaimer:
This summary is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional for personal medical guidance.